Načítá se...
The Eltrombopag antitumor effect on hepatocellular carcinoma
Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. In these cases, sorafenib is likely effective if given in combination with treatments that increase the numb...
Uloženo v:
| Vydáno v: | Int J Oncol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4599203/ https://ncbi.nlm.nih.gov/pubmed/26397763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2015.3180 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|